Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.

MLA

Zhang, Xiuying, et al. “Metagenomic Analysis Reveals Crosstalk between Gut Microbiota and Glucose-Lowering Drugs Targeting the Gastrointestinal Tract in Chinese Patients with Type 2 Diabetes: A 6 Month, Two-Arm Randomised Trial.” Diabetologia, vol. 65, no. 10, Oct. 2022, pp. 1613–26. EBSCOhost, https://doi.org/10.1007/s00125-022-05768-5.

APA

Zhang, X., Ren, H., Zhao, C., Shi, Z., Qiu, L., Yang, F., Zhou, X., Han, X., Wu, K., Zhong, H., Li, Y., Li, J., & Ji, L. (2022). Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial. Diabetologia, 65(10), 1613–1626. https://doi.org/10.1007/s00125-022-05768-5

Chicago

Zhang, Xiuying, Huahui Ren, Cuiling Zhao, Zhun Shi, Li Qiu, Fangming Yang, Xianghai Zhou, et al. 2022. “Metagenomic Analysis Reveals Crosstalk between Gut Microbiota and Glucose-Lowering Drugs Targeting the Gastrointestinal Tract in Chinese Patients with Type 2 Diabetes: A 6 Month, Two-Arm Randomised Trial.” Diabetologia 65 (10): 1613–26. doi:10.1007/s00125-022-05768-5.